Slides From Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic Goals in Type 2 Diabetes

Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: September 1, 2020 Expired: August 31, 2021

Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

John J. Russell, MD Neil Skolnik, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Nurse Practitioners: 1.0 AANP contact hour Released: July 13, 2020 Expired: July 12, 2021

Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.

CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)

Anne Peters, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: June 8, 2020 Expired: June 7, 2021